Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can immune cells predict herpesvirus danger in transplant patients?

NCT ID NCT05532540

Knowledge-focused Sponsor: Susanne Dam Nielsen, MD, DMSc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study looks at how the immune system's T cells respond to two common herpesviruses—cytomegalovirus (CMV) and varicella-zoster virus (VZV)—in people who have had a liver transplant. Because transplant recipients take drugs that suppress their immune system to prevent organ rejection, these viruses can reactivate and cause serious infections. By analyzing blood samples from 80 liver transplant patients, researchers hope to understand which immune responses protect against these infections and identify those at highest risk, potentially guiding future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
No drug or intervention is being tested; this is an observational study of immune responses.
What this could lead to
If successful, this could identify patients at high risk for herpesvirus infections and pave the way for new treatments to prevent CMV and VZV complications after liver transplant.
What could go wrong
This is an observational study, so it won't directly test any treatment. The findings may not immediately translate into new therapies, and the small sample size (80 participants) may limit how broadly the results apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Jan 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All adults enlisted for liver transplantation at Copenhagen University Hospital - Rigshospitalet (N = around 60 per year) will be invited to participate.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Enlisted for liver transplantation at Copenhagen University Hospital - Rigshospitalet * Aged 18 years or older Exclusion Criteria: * Inability to understand the study information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chickenpox chronic liver failure cytomegalovirus infection Inflammation varicella zoster infection Varicella Zoster Virus Infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus infections Liver transplant; complications Varicella zoster virus infection

Contacts and locations

Locations

  • Department of Health Technology, Technical University of Denmark

    Lyngby, 2800, Denmark

  • Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet

    Copenhagen, 2100, Denmark

  • Department of Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet

    Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.